Although several studies advanced the potential of TLR3 as a therapeutic target for hepatoma, melanoma, and clear cell renal carcinoma [20, 33–35], the mechanisms mediating its antitumor effects remain insufficiently characterized [36]. This evidence concerns the gene TLR3 and clear cell renal carcinoma.